A major grant from Centene's foundation aims to tackle housing insecurity for justice-involved individuals in Chicago, spotlighting the healthcare giant's community investments as its stock faces persistent headwinds.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
A dramatic sell-off in precious metals, led by a record-breaking drop in silver, rattled financial markets on January 30, 2026, as a surging U.S. dollar and shifting expectations for Federal Reserve policy triggered a broad retreat from risk assets.
High Tide Inc. reported record quarterly revenue and profitability in its fiscal Q4 2025, fueled by robust Canadian retail growth. The company outlined aggressive store expansion plans and detailed integration efforts for its new German medical cannabis asset, while also signaling cautious optimism regarding potential U.S. market entry.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
While low-volatility stocks promise stability in turbulent markets, experts warn that their defensive appeal may mask underlying risks and missed opportunities for growth. We examine three such companies that investors might want to approach with caution.
The healthcare sector has surged 17.4% in six months, outpacing the S&P 500. While demographic trends fuel long-term growth, regulatory hurdles and valuation concerns demand selective investing. We analyze one company built for decades of returns and two where investors should tread carefully.
While Roth accounts dominate the retirement planning conversation, a closer look at current tax laws and long-term income strategies reveals a compelling case for prioritizing pre-tax contributions. We examine the data with an expert and explore what gold's historical returns tell us about diversification.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
Chemed Corporation (NYSE: CHE) has seen its share price soften recently, reigniting investor debate over whether the healthcare services provider is now undervalued. With the stock trading around $430, a significant gap exists against some fair value estimates, even as operational challenges in its VITAS and Roto-Rooter segments loom.
Shares of The Pennant Group (PNTG) have climbed 15% in recent months, yet remain below yearly highs. With a P/E ratio significantly above the industry average, analysts are divided on whether the stock's growth prospects justify its premium valuation.
Amid corporate restructuring fears, a professional with a substantial nest egg but no home equity grapples with the daunting math of early retirement, soaring healthcare costs, and an uncertain housing market.
